Breakthrough Technology Designed to Dramatically Improve In Vitro Fertilization Efficacy and Pregnancy Outcome by Addressing the

    Bottleneck of Assisted Reproduction:

    Embryonic Implantation Failure

  • Better in vitro fertilization results with enhanced genomic expression at the uterine surface

    Targeted Technology Offers Improved Intrauterine Bioavailability of Hormone that Maximizes Endometrial Genomic Biomarker Expression

    (Efficacy and Duration)

    About Us


    We are an accomplished team of scientists, physicians and business professionals who are focused upon improving pregnancy outcome in reproductive medicine. Our sole purpose is to resolve the problem of failed embryonic implantation (which is the main hurdle in achieving pregnancy in IVF) and ultimately encourage Single Embryo Transfer (SET) to obtain a healthy singleton pregnancy for an infertile couple.

    Improved Genomics and Sustained Endometrial Biomarker Expression, by utilizing Incintas' Targeted Therapeutic Technology

    compared to all conventional uterine preparation methods currently offered to women undergoing IVF, (iM injection, vaginal rings and perivaginal gels/tablets)

    Conventional methods of uterine preparation are inferior to Incintas' targeted (*Patented) method of intrauterine (IU) administration of hormone prior to embryo transfer.


    Incintas' bioengineered IU approach sustains endometrial biomarker expression up to four times longer by having the hormone administered where it needs to be....inside the uterus, not the bloodstream.


    Incintas' technology dramatically extends the Window of Implantation while not exceeding the IU upper threshold hormonal concentration limit that actually hinders embryonic implantation (similar to a contraceptive as occurs in all conventional uterine preparations within 2 days after administration).


    *Exclusive, patented administration of hormone into the human uterus, until year 2032, US Patent #9107696, (EU IP pending - PCT).

    Ever since pregnancy has been achieved artificially with the first test tube baby in 1978, everyone assumed that the manner in which we prepare the uterus for implantation of the transferred embryo is adequate. It is not.


    In fact, all the conventional ways of uterine prep create contraceptive levels of hormone inside the uterus very quickly; less than two days. After this point, implantation of the embryo is impossible, leaving most embryos floating within the uterus to die and never even reach the uterine lining (endometrium).


    Implantation of the embryo into the uterine lining is a complex, time-dependent phenomenon that often takes 4-5 days in normal pregnancy. It requires a precise concentration range of progesterone within the uterus in order for implantation to occur. Too little hormone: the embryo won't implant. Too much hormone: a contraceptive environement is created which inhibits implantation of the embryo making pregnancy impossible.


    In assisted reproduction it is necessary to artificially re-create a receptive uterus that occurs in normal healthy pregnancies so that the transferred embryo will implant into the uterine lining. Current IVF treatments involve uterine preparation methods (termed: "luteal support") that restrict the proper range and exposure of the necessary hormone (aka: "bioavailability") at the uterine surface and thereby reduce the required implantation time by two-thirds.


    It is no surprise that after four decades since the first IVF baby was born, we've only reached a 30% fertility plateau of success. Most importantly, it is necessary to realize that there is very little possibility of dramatically improving pregnancy outcome in IVF until the manner in which we prepare the uterus for embryonic implantation is remedied.




    The Incintas Advantage


    The Incintas Advantage is unlike any other uterine preparation method in assisted reproduction. Incintas has patented the rights to administer hormone to the inside of the uterus until year 2032, which allows the optimal concentration of hormone to be sustained within the uterus for several days. Incintas' proprietary time-released therapeutic does not create a contraceptive level of progesterone like all other luteal support products and mimics intrauterine hormonal concentrations of normal healthy pregnancies.


    Since Incintas' therapeutic is "targeted" to the inside of the uterus, it also doesn't create elevated serum levels of progesterone like all other products which often produce negative side effects of feeling "flushed", breast tenderness, irritability, among others.


    Our time-released therapeutic is administered where it needs to be (inside the uterus) in order to facilitate implantation of the embryo (the major hurdle in achieving pregnancy) to succeed in achieving a healthy, singleton pregnancy for the infertile couple.

  • Executive Partners

    On a mission to help millions of fertility challenged families

    Jesse Pizolato


    Founding Partner

    Michael Barton


    Founding Partner

    Harald F. Stock, PhD

    Strategic Advisor

    Business Development

    Kun Zoo Kim, MD

    Founding Partner

  • Scientific Partners

    The Experts Behind Incintas Therapeutics' Breakthrough Technology

    Carlo Bulletti, MD, CSO

    IVF Luminary

    Dr. Carlo Bulletti is Director of the Physiopathology Unit of Reproduction at Rimini General Hospital, University of Bologna, Italy. He has authored 10 medical text books, 130 medical book chapters and more than 160 scientific articles.


    Robert Taylor,

    MD, PhD, CMO

    Endometriosis Luminary

    Robert N. Taylor, MD PhD is
    Professor, Reproductive Endocrinology and Infertility
    University of Utah Health
    Obstetrics & Gynecology Research Network
    30 North 1900 East, Suite 2A242
    Salt Lake City, Utah USA 84132

    Sarah Berga, MD

    Medical Advisor



    Dr. Sarah Berga is

    Professor and Director, Division of Reproductive Endocrinology and Infertility, University of Utah and

    has written extensively on the science and physiopathology of infertility in men and women..